V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210030860 | 210011551 | 1.54 | 73.5 | Disease modification (D) | 2017-12-09 | 2017-12-26 | IBRUTINIB | Y | N | 210030029 | IBRUTINIB |
| 210030861 | 210035020 | 0 | 66 | Curative (C) | 2015-06-27 | 2015-07-04 | IBRUTINIB | N | N | 210030055 | IBRUTINIB |
| 210030862 | 210035020 | null | null | Curative (C) | 2018-05-13 | 2018-05-14 | IBRUTINIB | 2 | N | 210030055 | IBRUTINIB |
| 210030863 | 210011555 | 1.64 | null | Curative (C) | 2017-02-05 | 2017-02-19 | IBRUTINIB | N | null | 210030064 | IBRUTINIB |
| 210030864 | 210021402 | 1.74 | 60.3 | Disease modification (D) | 2018-12-01 | 2018-12-23 | IBRUTINIB | 02 | N | 210030067 | IBRUTINIB |
| 210030865 | 210011560 | 1.67 | null | Curative (C) | 2017-03-08 | 2017-06-11 | Rituximab | 2 | N | 210030095 | RITUXIMAB |
| 210030866 | 210011560 | 1.67 | 54.8 | Curative (C) | 2017-08-30 | 2018-06-27 | FCR | Y | N | 210030095 | FCR |
| 210030867 | 210011563 | 1.52 | 61 | Adjuvant (A) | 2015-11-19 | 2015-11-19 | Bendamustine+Rituximab(Sub Courses) | N | N | 210030129 | BENDAMUSTINE + RITUXIMAB |
| 210030868 | 210011565 | 1.7 | 84 | Curative (C) | 2018-06-28 | 2018-09-01 | Bendamustine+Rituximab(Sub Courses) | N | N | 210030136 | BENDAMUSTINE + RITUXIMAB |
| 210030869 | 210011568 | 1.59 | 40.2 | Curative (C) | 2016-06-30 | 2016-11-09 | Vincristine (weekly) | N | null | 210030141 | VINCRISTINE |
| 210030870 | 210011574 | 1.71 | 78.2 | Curative (C) | 2016-09-11 | 2016-09-16 | FLAIR Trial | N | N | 210030148 | FLAIR TRIAL |
| 210030871 | 210011577 | 1.57 | 68.5 | Curative (C) | 2017-03-25 | 2017-09-25 | FLAIR Trial | 1 | N | 210030161 | FLAIR TRIAL |
| 210030872 | 210011581 | null | 80 | Curative (C) | 2019-04-22 | 2019-04-29 | Vincristine (weekly) | 2 | N | 210030163 | VINCRISTINE |
| 210030873 | 210011585 | 1.62 | 75 | Palliative (P) | null | 2017-03-26 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | Y | N | 210030165 | FCR |
| 210030874 | 210031143 | 0.88 | 54.7 | null | 2015-04-24 | 2015-04-24 | Bendamustine+Rituximab(Sub Courses) | N | N | 210030174 | BENDAMUSTINE + RITUXIMAB |
| 210030875 | 210011586 | 1.63 | 41.8 | Adjuvant (A) | 2015-12-08 | 2015-12-10 | VINCRISTINE | 2 | N | 210030175 | VINCRISTINE |
| 210030876 | 210011589 | 1.75 | 88.3 | null | 2017-07-12 | 2017-07-12 | FLAIR Trial | N | N | 210030177 | FLAIR TRIAL |
| 210030877 | 210011590 | 1.78 | 72.9 | Palliative (P) | 2014-06-03 | 2014-09-18 | BENDAMUSTINE + RITUXIMAB | 02 | N | 210030184 | BENDAMUSTINE + RITUXIMAB |
| 210030878 | 210011591 | 0 | 62.9 | Curative (C) | 2018-07-11 | 2018-08-06 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | 210030192 | FCR |
| 210030879 | 210011594 | null | 80 | Curative (C) | null | 2018-09-25 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | Y | N | 210030204 | FCR |
| 210030880 | 210011597 | 1.65 | 64.3 | Curative (C) | 2018-04-19 | 2018-04-20 | FCR | 02 | N | 210030216 | FCR |
| 210030881 | 210011600 | null | null | null | null | 2018-05-11 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210030227 | FCR |
| 210030882 | 210011602 | 1.73 | 98 | Disease modification (D) | 2018-03-12 | 2018-04-16 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | 210030228 | FCR |
| 210030883 | 210011605 | 1.53 | 60.4 | Curative (C) | 2013-06-02 | 2013-12-12 | Bendamustine+Rituximab (1st Course) | N | N | 210030255 | BENDAMUSTINE + RITUXIMAB |
| 210030884 | 210011611 | null | 92 | Palliative (P) | 2015-05-09 | 2015-05-16 | FLAIR Trial | N | N | 210030275 | FLAIR TRIAL |
| 210030886 | 210011621 | 1.65 | null | Curative (C) | 2017-10-22 | 2017-10-22 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210030325 | FCR |
| 210030887 | 210011625 | 1.64 | null | Disease modification (D) | 2017-01-17 | 2017-01-21 | FLAIR Trial | 01 | N | 210030342 | FLAIR TRIAL |
| 210030888 | 210011629 | 1.6 | 80 | Palliative (P) | 2013-04-06 | 2013-07-13 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210030365 | FCR |
| 210030889 | 210011636 | 1.72 | 91.5 | Curative (C) | 2016-12-17 | 2017-01-22 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | N | N | 210030435 | FCR |
| 210030890 | 210011643 | 1.85 | 91 | Palliative (P) | 2017-01-17 | 2017-01-17 | FLAIR Trial | 01 | N | 210030441 | FLAIR TRIAL |
| 210030891 | 210011645 | 1.9 | 0 | Curative (C) | 2016-07-27 | 2016-08-27 | FCR | N | N | 210030443 | FCR |
| 210030892 | 210011651 | null | 89.6 | Curative (C) | null | 2019-04-19 | FCR Oral - Cycle 2 onwards | 02 | N | 210030500 | FCR |
| 210030893 | 210011653 | 1.76 | 119.7 | Palliative (P) | 2013-05-07 | 2013-07-08 | BENDAMUSTINE + RITUXIMAB | N | N | 210030516 | BENDAMUSTINE + RITUXIMAB |
| 210030894 | 210011661 | 1.77 | null | Neo-adjuvant (N) | 2016-01-05 | 2016-01-17 | FCR Oral - Cycle 2 onwards | N | N | 210030563 | FCR |
| 210030895 | 210011667 | 1.54 | 65 | Curative (C) | 2017-12-16 | 2017-12-16 | FCR | N | N | 210030592 | FCR |
| 210030896 | 210011668 | 1.67 | 86.8 | Palliative (P) | 2018-01-18 | 2018-01-22 | Vincristine (weekly) | 02 | Y | 210030604 | VINCRISTINE |
| 210030897 | 210011673 | 1.74 | 63.5 | Disease modification (D) | 2015-04-08 | 2015-11-18 | FCR | N | N | 210030624 | FCR |
| 210030898 | 210011678 | 1.67 | 60 | Disease modification (D) | 2016-10-14 | 2016-11-21 | BENDAMUSTINE + RITUXIMAB | N | N | 210030636 | BENDAMUSTINE + RITUXIMAB |
| 210030899 | 210011691 | 1.54 | 53.7 | Disease modification (D) | 2014-10-11 | 2014-12-09 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 2 | N | 210030760 | FCR |
| 210030900 | 210011694 | 1.63 | 79 | Adjuvant (A) | 2015-05-02 | 2017-08-04 | BENDAMUSTINE + RITUXIMAB | N | N | 210030786 | BENDAMUSTINE + RITUXIMAB |
| 210030901 | 210011701 | 1.6 | 53.7 | Disease modification (D) | 2014-12-28 | 2015-05-12 | FCR | 2 | N | 210030835 | FCR |
| 210030902 | 210011715 | 1.6 | 52 | Palliative (P) | 2018-11-08 | 2018-11-08 | FCR Oral - Cycle 1 | N | N | 210030947 | FCR |
| 210030903 | 210011723 | 1.79 | 83 | Palliative (P) | 2017-03-18 | 2017-03-28 | FLAIR Trial | 01 | N | 210031008 | FLAIR TRIAL |
| 210030904 | 210011728 | null | 79 | null | 2017-01-14 | 2017-01-14 | FLAIR Trial | N | null | 210031011 | FLAIR TRIAL |
| 210030905 | 210011730 | 1.8 | 91.5 | Curative (C) | 2014-10-23 | 2016-02-06 | Bendamustine+Rituximab (1st Course) | N | N | 210031025 | BENDAMUSTINE + RITUXIMAB |
| 210030906 | 210011751 | 1.54 | 68 | Palliative (P) | 2013-06-27 | 2013-08-29 | Bendamustine+Rituximab(Sub Courses) | 02 | N | 210031101 | BENDAMUSTINE + RITUXIMAB |
| 210030907 | 210011752 | 1.83 | 86.7 | Palliative (P) | 2018-12-28 | 2019-03-01 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 2 | N | 210031103 | FCR |
| 210030909 | 210011775 | null | 86 | Palliative (P) | null | 2014-10-03 | BENDAMUSTINE + RITUXIMAB | 02 | null | 210031207 | BENDAMUSTINE + RITUXIMAB |
| 210030910 | 210011778 | null | 69.8 | Not known (9) | null | 2017-10-28 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | 210031224 | FCR |
| 210030911 | 210031178 | 1.29 | null | Adjuvant (A) | 2013-05-22 | 2013-06-07 | Bendamustine+Rituximab(Sub Courses) | N | null | 210031265 | BENDAMUSTINE + RITUXIMAB |